Lercanidipino Tarbis

Lercanidipine, the active ingredient in Lercanidipino Tarbis, is a calcium channel blocker presented as a tablet for oral use. It lowers elevated blood pressure in adults with hypertension. GNH USA supplies Lercanidipino Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is indicated for the management of hypertension, acting on vascular smooth muscle to reduce systemic vascular resistance.

- Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary high blood pressure. - Isolated systolic hypertension: reduces elevated systolic pressure, particularly in older adults. - Secondary hypertension: assists in controlling blood pressure when caused by other underlying conditions.

Adverse reactions may occur with Lercanidipine therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: including angioedema or rash. - Cardiac arrhythmia: irregular heart rhythms. - Stevens‑Johnson syndrome: severe skin reaction.

When prescribing Lercanidipine, clinicians should consider several safety measures. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Liver function assessment: evaluate hepatic status before initiation. - Elderly patients: start at lower doses due to increased sensitivity. - Concomitant vasodilators: avoid abrupt combination that may cause profound hypotension. - Discontinuation: taper gradually rather than stopping suddenly. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Grapefruit juice: can elevate drug concentration. - Concurrent potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (beta‑blockers, ACE inhibitors): may enhance blood‑pressure‑lowering effect. - Diuretics: can potentiate orthostatic hypotension. - NSAIDs: may reduce antihypertensive efficacy. - Digoxin: possible increase in serum digoxin levels.